Mission Therapeutics CEO On Clinical Strategy For DUB Drugs
Anker Lundemose, CEO of UK-based Mission Therapeutics, outlines the company's emerging DUBs drug discovery platform on the sidelines of the recent BIO-Europe partnering conference in Berlin.
You may also be interested in...
Merck & Co. will build a new innovation hub in London – an act described by the UK government as a major strategic investment – despite widespread Brexit ambiguity and a potentially unstable economic situation ahead for the soon-to-be ex-EU nation.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’